Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma [Studio internazionale randomizzato, in doppio cieco, controllato, di fase II con Rindopepimut/GM-CSF e temozolomide in terapia adiuvante in pazienti con glioblastoma EGFRvIII-positivo sottoposto a resezione chirurgica, di diagnosi recente.]

Trial Profile

An International, Randomized, Double-Blind, Controlled Phase II Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma [Studio internazionale randomizzato, in doppio cieco, controllato, di fase II con Rindopepimut/GM-CSF e temozolomide in terapia adiuvante in pazienti con glioblastoma EGFRvIII-positivo sottoposto a resezione chirurgica, di diagnosi recente.]

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Aug 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rindopepimut (Primary) ; Keyhole limpet haemocyanin; Sargramostim; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms Irradiance
  • Most Recent Events

    • 12 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top